Tenaya Therapeutics (TNYA) News Today $0.46 +0.01 (+2.02%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025April 24 at 2:07 PM | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest Down 22.1% in MarchTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 11,220,000 shares, a decline of 22.1% from the February 28th total of 14,400,000 shares. Based on an average daily trading volume, of 3,700,000 shares, the short-interest ratio is presently 3.0 days. Currently, 8.4% of the shares of the stock are short sold.April 1, 2025 | marketbeat.comTenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Tenaya Therapeutics in a research note on Monday.April 1, 2025 | marketbeat.comTenaya data further builds TN-201 profile, says H.C. WainwrightApril 1, 2025 | markets.businessinsider.comTenaya says TN-201 well tolerated in Phase 1b/2 interim dataApril 1, 2025 | markets.businessinsider.comTenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual MeetingMarch 31, 2025 | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Buy" by AnalystsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been assigned a consensus rating of "Buy" from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price objectiMarch 30, 2025 | marketbeat.comSA Asks: Which small/mid-cap cardiology stocks are undervalued?March 28, 2025 | msn.comIs Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.comWhat is Chardan Capital's Forecast for TNYA FY2025 Earnings?Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for shares of Tenaya Therapeutics in a research note issued on Monday, March 24th. Chardan Capital analyst Y. Livshits now expects that the company will postMarch 28, 2025 | marketbeat.comTenaya Therapeutics Publishes Positive Preclinical Data for TN-201 Gene Therapy Targeting MYBPC3-Associated Hypertrophic CardiomyopathyMarch 26, 2025 | nasdaq.comTenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in MarchMarch 25, 2025 | insidermonkey.comTop 3 Insider Stock Buys in March—Are They Still Good in April? (TNYA)March 25, 2025 | insidertrades.comTenaya Therapeutics publishes preclinical data on TN-201 in cardiac functionMarch 24, 2025 | markets.businessinsider.comTenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happyMarch 24, 2025 | finance.yahoo.comTenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy ModelsMarch 24, 2025 | globenewswire.comTenaya Therapeutics files $300M mixed securities shelfMarch 22, 2025 | markets.businessinsider.comTenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific SessionMarch 19, 2025 | markets.businessinsider.comTenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific SessionMarch 19, 2025 | globenewswire.comTenaya Therapeutics (NASDAQ:TNYA) Given New $6.00 Price Target at Canaccord Genuity GroupCanaccord Genuity Group dropped their target price on Tenaya Therapeutics from $18.00 to $6.00 and set a "buy" rating on the stock in a research report on Thursday.March 14, 2025 | marketbeat.comTenaya Therapeutics price target lowered to $6 from $18 at CanaccordMarch 13, 2025 | markets.businessinsider.comMorgan Stanley Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)March 12, 2025 | markets.businessinsider.comTenaya Therapeutics price target lowered to $5 from $15 at Morgan StanleyMarch 12, 2025 | markets.businessinsider.comTenaya Therapeutics price target lowered to $5 from $18 at H.C. WainwrightMarch 12, 2025 | markets.businessinsider.comTenaya Therapeutics price target lowered to $9 from $18 at ChardanMarch 12, 2025 | markets.businessinsider.comTenaya Therapeutics Advances Gene Therapy PipelineMarch 12, 2025 | tipranks.comInsiders Are Loading Up on These 4 Biotech Stocks NowMarch 11, 2025 | 247wallst.comTenaya Therapeutics reports Q4 EPS (28c), consensus (31c)March 10, 2025 | markets.businessinsider.comTenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 10, 2025 | globenewswire.comGroup Gp Lp Column III Acquires 35,714,284 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) StockMarch 8, 2025 | insidertrades.comTenaya Therapeutics announces securities offeringMarch 6, 2025 | investing.comTenaya Therapeutics 75M share Spot Secondary priced at 70cMarch 4, 2025 | markets.businessinsider.comTenaya Therapeutics stock dives after pricing offering to raise $52.5 millionMarch 4, 2025 | msn.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of "Buy" by BrokeragesShares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have been given a consensus rating of "Buy" by the six research firms that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price target among broMarch 4, 2025 | marketbeat.comTenaya Therapeutics Announces Pricing of Public OfferingMarch 3, 2025 | globenewswire.comTenaya Therapeutics Announces Proposed Public OfferingMarch 3, 2025 | globenewswire.comTenaya Therapeutics to Participate in Upcoming March Investor ConferencesMarch 3, 2025 | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Buy" from AnalystsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been assigned an average recommendation of "Buy" from the six analysts that are currently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month prFebruary 7, 2025 | marketbeat.comH.C. Wainwright maintains buy rating on Tenaya Therapeutics stockFebruary 4, 2025 | msn.comTenaya Therapeutics receives $8M clinical grant from CIRMFebruary 3, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Tenaya Therapeutics (NASDAQ:TNYA)HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Monday.February 3, 2025 | marketbeat.comTenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative MedicineFebruary 3, 2025 | globenewswire.comTenaya Therapeutics announces option repricing to retain staffJanuary 29, 2025 | msn.comTD Cowen Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)January 22, 2025 | markets.businessinsider.comAnalysts Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) PT at $17.33Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have been given an average recommendation of "Buy" by the six brokerages that are presently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price objectJanuary 16, 2025 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest UpdateTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) was the target of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 12,420,000 shares, a decline of 25.6% from the December 15th total of 16,690,000 shares. Based on an average daily volume of 4,710,000 shares, the short-interest ratio is currently 2.6 days. Approximately 18.9% of the company's stock are sold short.January 15, 2025 | marketbeat.comPromising Advancements in Tenaya Therapeutics’ Cardiac Gene Therapy Justify Buy RatingJanuary 15, 2025 | markets.businessinsider.comTenaya Therapeutics: Promising Clinical Pipeline and Strategic Milestones Justify Buy RatingJanuary 15, 2025 | markets.businessinsider.comTenaya Therapeutics (NASDAQ:TNYA) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a report on Tuesday.January 14, 2025 | marketbeat.comTenaya Therapeutics: Promising Pipeline and Upcoming Data Releases Support Buy RatingJanuary 13, 2025 | markets.businessinsider.com Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address TNYA Media Mentions By Week TNYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TNYA News Sentiment▼0.000.72▲Average Medical News Sentiment TNYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TNYA Articles This Week▼12▲TNYA Articles Average Week Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Actuate Therapeutics News Today Cybin News Today Innate Pharma News Today Molecular Partners News Today Nanobiotix News Today LifeVantage News Today Aardvark Therapeutics News Today AC Immune News Today Tango Therapeutics News Today DiaMedica Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TNYA) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTop Picks for Trump’s Pro-Crypto AmericaJust Announced: What Trump’s Move Means for Crypto—Join Now 27 top names reveal urgent insights as Bitcoin ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
